Cargando…
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
Beyond the overall relapse-free survival (RFS) advantage demonstrated in randomized trials (RCT) of adjuvant anti-PD-1 immunotherapy in radically resected stage III–IV melanoma, key issues about subgroups of interest have been raised in recent years, with non-conclusive results when considering sing...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122382/ https://www.ncbi.nlm.nih.gov/pubmed/33881961 http://dx.doi.org/10.1080/21645515.2021.1902723 |